Ver Video de la Doctora Cristina Cruz : PM01183 ( Lurbinectidin ) in PARP Resistant Breast Cancer ( ESMO 16 ).
En definitiva que PM01183 Beneficiaría a las Pacientes con Cáncer de Mama Resistente y Tambien Beneficiaria a los Farmacos y Tratamientos de Terapia Standar que se usan hoy en Día .
Dr Cristina Cruz - Vall d'Hebron Instituto de Oncología, Barcelona, Spain
Dr Cruz speaks with ecancer at ESMO 2016 about trials for lurbinectidin in patients for whom PARP inhibition is no longer and option.
She describes the mechanisms by which resistance to other medications can be subverted by lurbinectidin, and reports its suitability even for tumours with resistance to standard therapy cisplatin.
Lurbinectidin is discussed further by Dr Judith Balmaña, who spoke with ecancer here.
Dr Judith Balmaña - Vall d'Hebron Instituto de Oncología, Barcelona, Spain
Dr Balmaña speaks with ecancer at ESMO 2016 about using lurbinectidin, a trabectidin analogue, in the treatment of breast cancer.
She describes its mechanism of action, aiming to use the resulting gene suppression and DNA damage selectively in tumour cells, and gives results of progression-free and overall survival among multiple patient cohorts.
Dr Balmaña outlines further research into the timing and exposure factors that may influence patient response to lurbinectidin, especially PARP inhibitors, and studies of its activity in other tumour sites.
Lurbinectidin was discussed further by Dr Cristina Cruz as a possible course of treatment in PARP inhibitor resistant patients.
Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin /// 2016 ESMO Congress .
PharmaMar abre la vía a un nuevo mercado: un fármaco en fase de investigación contra el cáncer de mama .
Alberto Vigario // El Economista // 11 Octubre 2016 .
...
En definitiva que PM01183 Beneficiaría a las Pacientes con Cáncer de Mama Resistente y Tambien Beneficiaria a los Farmacos y Tratamientos de Terapia Standar que se usan hoy en Día .
